Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058017 | 0.90 | GABRA5 (0.40) | SLCO1B1GABRA5TNK2PDE4DPDE7A | |
| SCHEMBL21058053 | 0.89 | LPAR1 (0.40) | SLCO1B1GABRA5TNK2KDM4CNPC1 | |
| SCHEMBL25423074 | 0.81 | GABRA5 (0.36) | SLCO1B1GABRA5NPC1RAB9AMEN1 | |
| SCHEMBL22436317 | 0.79 | SLCO1B1 (0.68) | SLCO1B1GABRA5TNK2MEN1KMT2A | |
| SCHEMBL30472638 | 0.78 | RAB9A (0.45) | SLCO1B1GABRA5RAB9AMEN1KMT2A | |
| SCHEMBL31008992 | 0.78 | KDM4C (0.36) | GABRA5PDE4DPDE7AKDM4CNPC1 | |
| SCHEMBL30740368 | 0.78 | TGFBR1 (0.44) | SLCO1B1GABRA5KDM4CNPC1RAB9A | |
| SCHEMBL22806839 | 0.78 | SLCO1B1 (0.41) | SLCO1B1GABRA5KDM4CNPC1RAB9A | |
| SCHEMBL24982985 | 0.78 | SLCO1B1 (0.39) | SLCO1B1KDM4CNPC1RAB9ATGFBR1 | |
| SCHEMBL22576664 | 0.77 | KDM4C (0.37) | SLCO1B1KDM4CNPC1RAB9ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| EP-4452965-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118253-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | SLCO1B1 2746/4885GABRA5 1335/4885TNK2 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.